Michel Detheux
Founder chez ITEOS THERAPEUTICS, INC.
Fortune : 803 437 $ au 31/03/2024
Profil
Michel Detheux is the founder of iTeos Therapeutics SA, founded in 2011, where he holds the title of President, Chief Executive Officer & Director.
He is also the founder of iTeos Therapeutics, Inc., founded in 2012, where he holds the title of President, Chief Executive Officer & Director.
Dr. Detheux's current job(s) include being the Independent Chairman at Ona Therapeutics SL since 2021 and the Chairman at Innoskel SASU since 2022.
Dr. Detheux's former job(s) include being the President, Chief Executive Officer & Director at Iteos Belgium SA, an Executive Director at Ogeda SA, and a Director at Ludwig Cancer Research.
Dr. Detheux obtained a doctorate degree from Université Catholique de Louvain.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
ITEOS THERAPEUTICS, INC.
0,16% | 07/03/2024 | 58 903 ( 0,16% ) | 803 437 $ | 31/03/2024 |
Postes actifs de Michel Detheux
| Sociétés | Poste | Début |
|---|---|---|
| ITEOS THERAPEUTICS, INC. | Founder | 01/04/2012 |
iTeos Therapeutics SA
 iTeos Therapeutics SA Pharmaceuticals: MajorHealth Technology iTeos Therapeutics SA engages in the discovery of immunomodulators for cancer therapy. It operates as a biotechnology company which focuses on targeting metabolism of the tumor microenvironment through development of small-molecule immunomodulators for cancer treatment. The firm develops small molecules designed to target the tumor microenvironment by inhibiting cancer-induced immune suppression. Targeting such resistance mechanisms will enhance the clinical efficacy of both standards of care treatments as well as the newer immunomodulatory therapies based on the blockade of immune checkpoints. The company was founded in 2011 by Michel Detheux and Benoit Van den Eynde and is headquartered in Gosselies, Belgium. | Founder | 01/01/2011 |
Ona Therapeutics SL
 Ona Therapeutics SL Pharmaceuticals: MajorHealth Technology Ona Therapeutics SL is a biotech company based in Barcelona, Spain that specializes in discovering and developing therapeutic biologics targeting tumor metastatic-initiating cells and lipid metabolism. The Spanish company's focus is on developing novel therapies against advanced cancer. The company was founded in 2019 by Salvador Aznar Benitah and Valerie Liesbeth Brigitte Vanhooren, with Valerie Liesbeth Brigitte Vanhooren serving as CEO since incorporation. | Chairman | 02/12/2021 |
Innoskel SASU
 Innoskel SASU BiotechnologyHealth Technology Innoskel SASU is a French bioscience platform company that aims to improve the quality of life of patients with severe rare bone disorders. Innoskel is based in Valbonne, France, and was founded by Elvire Gouze, who has been the CEO since incorporation. The company achieves this goal through patient centricity, scientific innovation, and operational excellence. Innoskel is developing transformative therapies for the unmet needs of individuals with rare bone disorders, with a focus on type II collagen disorders. The company's lead asset is INS-101, a gene therapy that has shown strong efficacy in preclinical studies. | Chairman | 12/04/2022 |
Anciens postes connus de Michel Detheux
| Sociétés | Poste | Fin |
|---|---|---|
| Ludwig Cancer Research | Director/Board Member | - |
Iteos Belgium SA
 Iteos Belgium SA Pharmaceuticals: MajorHealth Technology Iteos Belgium SA manufactures pharmaceutical raw materials. The private company is based in Gosselies, Belgium. | Chief Executive Officer | - |
Ogeda SA
 Ogeda SA Pharmaceuticals: MajorHealth Technology Ogeda SA discovers and develops small molecule drugs. It develops NK3 antagonists for the treatment of hormone-dependent pathologies in the field of Women's Health. The company was founded in 1994 and is headquartered in Gosselies, Spain. | Director/Board Member | - |
Formation de Michel Detheux
| Université Catholique de Louvain | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| ITEOS THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 6 |
|---|---|
Ogeda SA
Ogeda SA Pharmaceuticals: MajorHealth Technology Ogeda SA discovers and develops small molecule drugs. It develops NK3 antagonists for the treatment of hormone-dependent pathologies in the field of Women's Health. The company was founded in 1994 and is headquartered in Gosselies, Spain. | Health Technology |
iTeos Therapeutics SA
iTeos Therapeutics SA Pharmaceuticals: MajorHealth Technology iTeos Therapeutics SA engages in the discovery of immunomodulators for cancer therapy. It operates as a biotechnology company which focuses on targeting metabolism of the tumor microenvironment through development of small-molecule immunomodulators for cancer treatment. The firm develops small molecules designed to target the tumor microenvironment by inhibiting cancer-induced immune suppression. Targeting such resistance mechanisms will enhance the clinical efficacy of both standards of care treatments as well as the newer immunomodulatory therapies based on the blockade of immune checkpoints. The company was founded in 2011 by Michel Detheux and Benoit Van den Eynde and is headquartered in Gosselies, Belgium. | Health Technology |
Ona Therapeutics SL
Ona Therapeutics SL Pharmaceuticals: MajorHealth Technology Ona Therapeutics SL is a biotech company based in Barcelona, Spain that specializes in discovering and developing therapeutic biologics targeting tumor metastatic-initiating cells and lipid metabolism. The Spanish company's focus is on developing novel therapies against advanced cancer. The company was founded in 2019 by Salvador Aznar Benitah and Valerie Liesbeth Brigitte Vanhooren, with Valerie Liesbeth Brigitte Vanhooren serving as CEO since incorporation. | Health Technology |
Innoskel SASU
Innoskel SASU BiotechnologyHealth Technology Innoskel SASU is a French bioscience platform company that aims to improve the quality of life of patients with severe rare bone disorders. Innoskel is based in Valbonne, France, and was founded by Elvire Gouze, who has been the CEO since incorporation. The company achieves this goal through patient centricity, scientific innovation, and operational excellence. Innoskel is developing transformative therapies for the unmet needs of individuals with rare bone disorders, with a focus on type II collagen disorders. The company's lead asset is INS-101, a gene therapy that has shown strong efficacy in preclinical studies. | Health Technology |
Iteos Belgium SA
Iteos Belgium SA Pharmaceuticals: MajorHealth Technology Iteos Belgium SA manufactures pharmaceutical raw materials. The private company is based in Gosselies, Belgium. | Health Technology |
| Ludwig Cancer Research |
